

ESTTA Tracking number: **ESTTA734484**

Filing date: **03/18/2016**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Notice of Opposition

Notice is hereby given that the following party opposes registration of the indicated application.

Opposer Information

Name	Apotex Technologies Inc.
Granted to Date of previous extension	03/23/2016
Address	150 Signet Drive Toronto, ON M9L1T9 CANADA

Attorney information	Sheryl De Luca Nixon & Vanderhye P.C. 901 N. Glebe Road, 11th Floor Arlington, VA 22203 UNITED STATES nixonptomail@nixonvan.com, sld@nixonvan.com, rar@nixonvan.com
----------------------	--

Applicant Information

Application No	86683619	Publication date	11/24/2015
Opposition Filing Date	03/18/2016	Opposition Period Ends	03/23/2016
Applicant	Microdermis Corporation 103 Carnegie Center, Suite 300 Princeton, NJ 08540 UNITED STATES		

Goods/Services Affected by Opposition

Class 005. First Use: 2015/04/22 First Use In Commerce: 2015/06/06 All goods and services in the class are opposed, namely: Topical first aid cream
--

Grounds for Opposition

Priority and likelihood of confusion	Trademark Act section 2(d)
--------------------------------------	----------------------------

Marks Cited by Opposer as Basis for Opposition

U.S. Registration No.	2859839	Application Date	08/25/2003
Registration Date	07/06/2004	Foreign Priority Date	NONE
Word Mark	APO		

Design Mark	
Description of Mark	NONE
Goods/Services	Class 005. First use: First Use: 1975/03/00 First Use In Commerce: 1997/09/00 Medicinal and pharmaceutical preparations, namely, psychotherapeutics (antidepressants, tranquilizers); antiparkinsonians; antidiabetics; [vitamins and mineral dietary supplements;] diuretics; antihypertensives; sedatives; antiemetics; antibacterials; antibiotics; antiarthritics; anti-inflammatory agents; anticonvulsants; antiarrhythmics; uricosurics; xanthine oxidase inhibitors

U.S. Registration No.	1162404	Application Date	03/15/1978
Registration Date	07/28/1981	Foreign Priority Date	NONE
Word Mark	APOTEX		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 005. First use: First Use: 0 First Use In Commerce: 0 Medicinal and Pharmaceutical Preparations		

U.S. Registration No.	4632563	Application Date	02/25/2013
Registration Date	11/04/2014	Foreign Priority Date	NONE
Word Mark	APOBIOLOGIX A DIVISION OF APOTEX CORP.		
Design Mark			
Description of Mark	The mark consists of the stylized figure of a human being to the left of a stylized rendering of the word "ApoBiologix" with the letters "A" and "B" presented in initial caps and the remaining letters presented in lower case lettering. Beneath separated by a horizontal line the length of the wording and flush to the right is the wording "A Division of Apotex Corp." in a smaller font with the letters "A", "D", and "C" in the wording featured in initial caps and the remaining letters in lower case.		
Goods/Services	Class 042. First use: First Use: 2014/08/18 First Use In Commerce: 2014/08/18 Drug product research development services		

U.S. Registration No.	4621329	Application Date	02/25/2013
Registration Date	10/14/2014	Foreign Priority Date	NONE
Word Mark	APOBIOLOGIX		
Design Mark			
Description of Mark	The mark consists of the stylized figure of a human being to the left of a stylized rendering of the word "ApoBiologix" with the letters "A" and "B" presented in initial caps and the remaining letters presented in lower case lettering.		
Goods/Services	Class 042. First use: First Use: 2014/08/18 First Use In Commerce: 2014/08/18 Drug product research development services		

U.S. Application No.	85926345	Application Date	05/08/2013
Registration Date	NONE	Foreign Priority Date	05/07/2013
Word Mark	APOBIOLOGIX		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 042. First use: First Use: 0 First Use In Commerce: 0 Drug product research development services		

U.S. Application No.	86528589	Application Date	02/09/2015
Registration Date	NONE	Foreign Priority Date	NONE
Word Mark	APOTEX CONSUMER PRODUCTS		

Design Mark	<h1>APOTEX CONSUMER PRODUCTS</h1>		
Description of Mark	NONE		
Goods/Services	<p>Class 016. First use: First Use: 0 First Use In Commerce: 0 Printed brochures, catalogs and promotional materials in the nature of pamphlets and flyers all relating to pharmaceutical products</p> <p>Class 035. First use: First Use: 0 First Use In Commerce: 0 Promoting the pharmaceutical products of others by advertising and marketing</p> <p>Class 042. First use: First Use: 0 First Use In Commerce: 0 Drug and pharmaceutical product research and development services</p>		

U.S. Application No.	86560396	Application Date	03/11/2015
Registration Date	NONE	Foreign Priority Date	03/05/2015

Word Mark	APOBIOLOGIX		
Design Mark	<h1>ApoBiologix</h1>		
Description of Mark	NONE		
Goods/Services	<p>Class 005. First use: First Use: 0 First Use In Commerce: 0 Pharmaceutical preparations namely, pharmaceuticals for hemopoetic growth factors used for stimulating white blood cellproduction and for the treatment of proliferative disorders, namely, angiogenicdisorders including cancer</p>		

Attachments	76540417#TMSN.png(bytes) 76713573#TMSN.png(bytes) 76713572#TMSN.png(bytes) 85926345#TMSN.png(bytes) 86528589#TMSN.png(bytes) 86560396#TMSN.png(bytes) 2148-140.notice of opposition.pdf(294432 bytes) Exhibit 1 - Reg. No. 2859839 .pdf(50523 bytes)
-------------	---

	Exhibit 2 - Reg. No. 1162404_.pdf(38066 bytes) Exhibit 3 - Reg. No. 4634563_.pdf(1998489 bytes) Exhibit 4 - Reg. No. 4621329_.pdf(1837715 bytes)
--	---

Certificate of Service

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Signature	/Sheryl De Luca/
Name	Sheryl De Luca
Date	03/18/2016

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

2148-140

Apotex Technologies Inc.,)	
)	
Opposer,)	
)	
v.)	Opposition No. _____
)	Application No. 86/683,619
Microdermis Corporation,)	Mark: APOCREME
)	
Applicant.)	

ATTN: Chief Administrative Trademark Judge
Commissioner for Trademarks
P.O. Box 1451
Alexandria, Virginia 22313-1451

NOTICE OF OPPOSITION

In the matter of an application for registration of the mark APOCREME, Serial No. 86/683,619, filed July 6, 2015 by Microdermis Corporation (hereafter "Applicant"), which was published in the Official Gazette of November 24, 2015 in International Class 5, Apotex Technologies Inc., with an address at 150 Signet Drive, Toronto, Ontario Canada M9L1T9 (hereafter "Opposer"), believes that it will be damaged by the registration of the mark shown in the above-identified application and hereby opposes same under the provisions of Section 13 of the Trademark Act of July 5, 1945 (15 U.S.C. §1063). Our payment in the amount of \$300 is enclosed.

As grounds for opposition, it is alleged that:

1. Opposer adopted the mark "APO" in 1975 for various medicinal and pharmaceutical preparations in International Class 5 and has used the mark APO for these goods in commerce since at least as early as 1997.

2. Opposer owns and relies on incontestable U.S. Trademark Registration No. 2859839 for the trademark APO for "Medicinal and pharmaceutical preparations, namely, psychotherapeutics (antidepressants, tranquilizers); antiparkinsonians; antidiabetics; diuretics; antihypertensives; sedatives; antiemetics; antibacterials; antibiotics; antiarthritics; anti-inflammatory agents; anticonvulsants; antiarrhythmics; uricosurics; xanthine oxidase inhibitors," in Class 5.
3. Registration No. 2859839 was filed on August 25, 2003, issued on July 6, 2004 and claims a first date of use anywhere of March 1975 and first date of use in commerce of September 1997. This registration is valid, subsisting, unrevoked and uncanceled; as such, this registration constitutes *conclusive* evidence of the validity of the registered mark and of the registration thereof, and of Opposer's ownership of the mark shown therein, and of Opposer's exclusive right to use the registered mark in commerce as provided in Section 33 of the Trademark Act. Opposer's '839 Registration also constitutes notice to Applicant of Opposer's claim of ownership of the mark shown therein as provided in Sections 7(b), 22, and 33(a) of the Trademark Act. A true and correct copy of the specifics of the '839 Registration obtained from the PTO's TESS database is attached hereto as Exhibit 1 and made of record.
4. Opposer owns and relies on U.S. Trademark Registration No. 1162404 for the trademark APOTEX for "Medicinal and Pharmaceutical Preparations," in Class 5.
5. Registration No. 1162404 was filed on March 15, 1978 and was issued on July 28, 1981. This registration is valid, subsisting, unrevoked and uncanceled; as such, this registration constitutes *prima facie* evidence of the validity of the

registered mark and of the registration thereof, and of Opposer's ownership of the mark shown therein, and of Opposer's exclusive right to use the registered mark in commerce as provided in Section 33 of the Trademark Act. Opposer's '404 Registration also constitutes notice to Applicant of Opposer's claim of ownership of the mark shown therein as provided in Sections 7(b), 22, and 33(a) of the Trademark Act. A true and correct copy of the specifics of the '404 Registration obtained from the PTO's TESS database is attached as Exhibit 2 and made of record.

6. Opposer owns and relies on U.S. Trademark Registration No. 4632563 for the



trademark for "Drug product research development services," in Class 42.

7. Registration No. 4632563 was filed on February 25, 2013, was issued on November 4, 2014 and claims a date of first use anywhere and a date of first use in commerce of August 18, 2014. This registration is valid, subsisting, unrevoked and uncanceled; as such, this registration constitutes *prima facie* evidence of the validity of the registered mark and of the registration thereof, and of Opposer's ownership of the mark shown therein, and of Opposer's exclusive right to use the registered mark in commerce as provided in Section 33 of the Trademark Act. Opposer's '563 Registration also constitutes notice to Applicant of Opposer's claim of ownership of the mark shown therein as provided in Sections 7(b), 22, and 33(a) of the Trademark Act. A true and correct copy of the specifics of the

'563 Registration obtained from the PTO's TESS database is attached as Exhibit 3 and made of record.

8. Opposer owns and relies on U.S. Trademark Registration No. 4621329 for the

trademark  for "Drug product research development services," in Class 42.

9. Registration No. 4621329 was filed on February 25, 2013, was issued on October 14, 2014 and claims a date of first use anywhere and a date of first use in commerce of August 18, 2014. This registration is valid, subsisting, unrevoked and uncanceled; as such, this registration constitutes *prima facie* evidence of the validity of the registered mark and of the registration thereof, and of Opposer's ownership of the mark shown therein, and of Opposer's exclusive right to use the registered mark in commerce as provided in Section 33 of the Trademark Act. Opposer's '329 Registration also constitutes notice to Applicant of Opposer's claim of ownership of the mark shown therein as provided in Sections 7(b), 22, and 33(a) of the Trademark Act. A true and correct copy of the specifics of the '329 Registration obtained from the PTO's TESS database is attached as Exhibit 4 and made of record.

10. Opposer is also the owner of prior pending Application Serial No. 85926345 for the mark APOBIOLOGIX for "Drug product research development services," in Class 42. This was filed on May 8, 2013.

11. Opposer is also the owner of prior pending Application Serial No. 86528589 for the mark APOTEX CONSUMER PRODUCTS for "Printed brochures, catalogs and promotional materials in the nature of pamphlets and flyers all relating to

pharmaceutical products,” in Class 16; “Promoting the pharmaceutical products of others by advertising and marketing,” in Class 35; and “Drug and pharmaceutical product research and development services,” in Class 42. This was filed on February 9, 2015.

12. Opposer is also the owner of prior pending Application Serial No. 86560396 for the mark APOBIOLOGIX for “Pharmaceutical preparations namely, pharmaceuticals for hemopoetic growth factors used for stimulating white blood cell production and for the treatment of proliferative disorders, namely, angiogenic disorders including cancer,” in Class 5. This was filed on March 11, 2015.
13. In addition to its federal rights, Opposer has common law rights in its APO and APO-derivative marks in connection with medicinal and pharmaceutical preparations and drug product research development services.
14. Since at least as early as September 14, 2012, Opposer has adopted and used the mark APOTEX on the packing of its Imiquimod cream 5% sold as a pharmaceutical product in the United States.
15. Since at least as early as 1997, Opposer has also stamped the mark “APO” on many of its pharmaceutical capsules and tablets sold in the United States.
16. On July 6, 2015, Applicant filed an application for the mark APOCREME for “topical first aid cream” (“Applicant’s Goods”). The application was assigned Serial No. 86/683,619.
17. Applicant’s filing to register APOCREME in connection with Applicant’s Goods is without the consent or permission of Opposer.

18. Applicant's APOCREME mark of Application Serial No. 86/683,619 for Applicant's Goods so resembles Opposer's APO and APO-derivative trademarks as to be likely to cause confusion, mistake or deception within the meaning of Section 2(d) of the Trademark Act.
19. Applicant is attempting to register the confusingly similar APOCREME trademark for identical and/or highly related goods in Class 5 in the same channels of trade to the same targeted customers as those of Opposer for its APO and APO-derivative marks for Opposer's products and services.
20. The subject matter of Applicant's Goods identified in Application Serial No. 86/683,619 is in the exact same and/or highly related fields as Opposer's goods and services under its APO and APO-derivative marks.
21. Application Serial No. 86/683,619 is based on a use in commerce filing basis. Applicant's alleged first date of use of April 22, 2015 and first date of use in commerce of June 6, 2015, is well after Opposer's first date of use and use in commerce of its APO and APOTEX marks of Registration Nos. 2859839, 1162404, 4632563, 4621329 and Opposer's common law uses of APO and APOTEX marks in connection with Opposer's goods and services.
22. On information and belief, Applicant made no use of the mark APOCREME of Application Serial No. 86/683,619 prior to the filing of Opposer's Registration Nos. 2859839, 1162404, 4634563 or 4621329 or prior to the filing of Opposer's Application Nos. 85926345, 86528589 or 86560396.
23. On information and belief, Applicant made no use of the mark APOCREME of Application Serial No. 86/683,619 prior to Opposer's first date of use of

Opposer's APO and APO-Derivative trademarks of Registration Nos. 2859839, 1162404, 4634563 and 4621329.

24. On information and belief, Applicant made no use of the mark APOCREME of Serial No. 86/683,619 prior to Opposer's first date of use in commerce of Opposer's APO and APO-Derivative trademarks of Registration Nos. 2859839, 1162404, 4634563 and 4621329.

25. The parties' goods are sold in the same channels of trade.

26. By virtue of Opposer's prior use, advertising and sale of goods and services under its APO and APO-derivate trademarks, and its maintenance of high quality standards relating thereto, the public has come to recognize the trademarks of Registration Nos. 2859839, 1162404, 4634563 and 4621329 and its common law APO and APO-derivative marks as indications of origin in Opposer, as a consequence of which Opposer has established valuable goodwill and exclusive rights in its APO and APO-derivative trademarks.

27. The mark APO of Registration No. 2859839, APOTEX of Registration No. 1162404, APOBIOLOGIX A DIVISION OF APOTEX CORP. & design of Registration No. 4632563, APOBIOLOGIX & Design of Registration No. 4,621,329, APOBIOLOGIX of Application No. 85926345, APOTEX CONSUMER PRODUCTS of Application No. 86528589, APOBIOLOGIX of Application No. 86560396, and applicant's APO and APO-derivative common law marks and the mark APOCREME of Application Serial No. 86/683,619 have the same or highly similar connotations when the marks are considered as a whole.

28. The terms "APO," "APOTEX," "APOBIOLOGIX" and "APOCREME" have similar appearances, pronunciations and connotations and commercial impressions.
29. The mark APO of Registration No. 2859839, APOTEX of Registration No. 1162404, APOBIOLOGIX A DIVISION OF APOTEX CORP. & design of Registration No. 4632563, APOBIOLOGIX & Design of Registration No. 4,621,329, APOBIOLOGIX of Application No. 85926345, APOTEX CONSUMER PRODUCTS of Application No. 86528589 APOBIOLOGIX of Application No. 86560396, and Opposer's APO and APO-derivative common law marks and the mark APOCREME of Application Serial No. 86/683,619 are identical in part in that each include the identical term APO.
30. The element CREME of Applicant's mark is a descriptive word for Applicant's type of goods and does not distinguish Applicants mark from Opposer's APO and APO-derivative marks.
31. Opposer's goods and services sold under its APO and APO-derivative marks and Applicants goods sold or offered under the mark APOCREME are virtually identical and/or highly related goods and services, which are or are likely to be offered through the same or overlapping channels of trade to the same or overlapping classes of purchasers so that purchasers, prospective purchasers, users and others are likely to be confused, mistaken or deceived into the belief, contrary to fact, that Applicant's Goods offered under the mark APOCREME emanate from and/or are in some way sponsored or approved by Opposer or are otherwise related to Opposer's goods under its APO and APO-derivative marks, thereby damaging Opposer.

32. Applicant is not lawfully entitled to the registration which it seeks for the reason, *inter alia*, that the mark APOCREME as used or intended for use for Applicant's Goods so resembles Opposer's previously used and registered marks as to be likely to cause confusion, to cause mistake or to deceive within the meaning of Section 2(d) of the Federal Trademark Act, thereby damaging Opposer.

WHEREFORE, Opposer prays that the present opposition be sustained and the registration of APOCREME sought by Applicant be refused.

Respectfully submitted,
Apotex Technologies Inc.

Dated: March 18, 2016


By: Sheryl De Luca

Sheryl De Luca, Esq.
Robert Rowan, Esq.
NIXON & VANDERHYE P.C.
901 North Glebe Road, 11th Floor
Arlington, Virginia 22201
Tel: 703-816-4000
Fax: 703-816-4100

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing "Notice of Opposition" was served upon Applicant at the address below, by first class mail this 18th day of March 2016:

JAMES E. ROSINI
Kenyon & Kenyon Llp
1 Broadway
New York, NY 10004-1007



Sheryl De Luca

EXHIBIT 1

Generated on: This page was generated by TSDR on 2016-03-18 15:19:50 EDT

Mark: APO

APO

US Serial Number: 76540417

Application Filing Date: Aug. 25, 2003

US Registration Number: 2859839

Registration Date: Jul. 06, 2004

Register: Principal

Mark Type: Trademark

Status: The registration has been renewed.

Status Date: Jun. 27, 2014

Publication Date: Apr. 13, 2004

Mark Information

Mark Literal Elements: APO

Standard Character Claim: No

Mark Drawing Type: 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Medicinal and pharmaceutical preparations, namely, phychotherapeutics (antidepressants, tranquillizers); antiparkinsonians; antidiabetics; [vitamins and mineral dietary supplements;] diuretics; antihypertensives; sedatives; antiemetics; antibacterials; antibiotics; antiarthritics; anti-inflammatory agents; anticonvulsants; antiarrhythmics; uricosurics; xanthine oxidase inhibitors

International Class(es): 005 - Primary Class

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: 1(a)

First Use: Mar. 1975

Use in Commerce: Sep. 1997

Basis Information (Case Level)

Filed Use: Yes

Currently Use: Yes

Amended Use: No

Filed ITU: No

Currently ITU: No

Amended ITU: No

Filed 44D: No

Currently 44D: No

Amended 44D: No

Filed 44E: No

Currently 44E: No

Amended 44E: No

Filed 66A: No

Currently 66A: No

Filed No Basis: No

Currently No Basis: No

Current Owner(s) Information

Owner Name: APOTEX TECHNOLOGIES, INC.

Owner Address: 150 SIGNET DRIVE
TORONTO, ONTARIO M9L 1T9
CANADA

Legal Entity Type: CORPORATION

State or Country: CANADA

Where Organized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Robert W. Adams

Docket Number: 2148-69

Correspondent

Correspondent Name/Address: ROBERT W. ADAMS
NIXON & VANDERHYE, P.C.
901 NORTH GLEBE RD.
11TH FLOOR
ARLINGTON, VIRGINIA 22203-1808
UNITED STATES

Phone: 703-816-4022

Fax: 703-816-4100

Correspondent e-mail: fbe@nixonvan.com nixonptomail@nixonvan.com

Correspondent e-mail Authorized: Yes

Domestic Representative

Domestic Representative Name: Robert W. Adams

Phone: 703-816-4022

Fax: 703-816-4100

Domestic Representative e-mail: fbe@nixonvan.com

Domestic Representative e-mail Authorized: Yes

Prosecution History

Date	Description	Proceeding Number
Jun. 27, 2014	NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED	
Jun. 27, 2014	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	69471
Jun. 27, 2014	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	69471
Jun. 26, 2014	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	69471
Jun. 10, 2014	TEAS SECTION 8 & 9 RECEIVED	
Jul. 28, 2010	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	64591
Jul. 06, 2010	REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED	64591
Jul. 06, 2010	REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED	64591
Jul. 27, 2010	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	64591
Jul. 06, 2010	PAPER RECEIVED	
Jul. 06, 2009	TEAS CHANGE OF CORRESPONDENCE RECEIVED	
Jul. 06, 2004	REGISTERED-PRINCIPAL REGISTER	
Apr. 13, 2004	PUBLISHED FOR OPPOSITION	
Mar. 24, 2004	NOTICE OF PUBLICATION	
Feb. 06, 2004	APPROVED FOR PUB - PRINCIPAL REGISTER	
Feb. 05, 2004	ASSIGNED TO EXAMINER	76936

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Affidavit of Incontestability: Section 15 - Accepted

Renewal Date: Jul. 06, 2014

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: GENERIC WEB UPDATE

Date in Location: Jun. 27, 2014

Assignment Abstract Of Title Information

Summary

Total Assignments: 1

Registrant: APOTEX INC.

Assignment 1 of 1

Conveyance: ASSIGNS THE ENTIRE INTEREST

Reel/Frame: [3198/0369](#)

Pages: 4

Date Recorded: Nov. 22, 2005

Supporting Documents: [assignment-tm-3198-0369.pdf](#)

Assignor

Name: [APOTEX, INC.](#)

Execution Date: Nov. 18, 2005

Legal Entity Type: CORPORATION

State or Country: CANADA
Where Organized:

Assignee

Name: [APOTEX TECHNOLOGIES, INC.](#)

Legal Entity Type: CORPORATION

State or Country: CANADA
Where Organized:

Address: 150 SIGNET DRIVE
TORONTO, ONTARIO, CANADA M9L 1T9

Correspondent

Correspondent Name: ROBERT W. ADAMS

Correspondent Address: 901 NORTH GLEBE ROAD
11TH FLOOR
ARLINGTON, VA 22203-1808

Domestic Representative

Domestic Representative Name: ROBERT W. ADAMS

Domestic Representative Address: 901 NORTH GLEBE ROAD
11TH FLOOR
ARLINGTON, VA 22203-1808

Int. Cl.: 5

Prior U.S. Cls.: 6, 18, 44, 46, 51 and 52

Reg. No. 2,859,839

United States Patent and Trademark Office

Registered July 6, 2004

**TRADEMARK
PRINCIPAL REGISTER**

APO

APOTEX INC. (CANADA CORPORATION)
150 SIGNET DRIVE
TORONTO, ONTARIO, CANADA M9L 1T9

FOR: MEDICINAL AND PHARMACEUTICAL
PREPARATIONS, NAMELY PSYCHOTHERAPEU-
TICS (ANTIDEPRESSANTS, TRANQUILLIZERS);
ANTIPARKINSONIANS; ANTIDIABETICS; VITA-
MINS AND MINERAL DIETARY SUPPLEMENTS;
DIURETICS; ANTIHYPERTENSIVES; SEDATIVES;
ANTIEMETICS; ANTIBACTERIALS; ANTIBIOTICS;

ANTIARTHRITICS; ANTI-INFLAMMATORY
AGENTS; ANTICONVULSANTS; ANTIARRHYTH-
MICS; URICOSURICS; XANTHINE OXIDASE INHI-
BITORS, IN CLASS 5 (U.S. CLS. 6, 18, 44, 46, 51 AND
52).

FIRST USE 3-0-1975; IN COMMERCE 9-0-1997.

SER. NO. 76-540,417, FILED 8-25-2003.

GWEN STOKOLS, EXAMINING ATTORNEY

EXHIBIT 2

Generated on: This page was generated by TSDR on 2016-03-18 15:21:36 EDT

Mark: APOTEX

US Serial Number: 73162271

Application Filing Date: Mar. 15, 1978

US Registration Number: 1162404

Registration Date: Jul. 28, 1981

Register: Principal

Mark Type: Trademark

Status: The registration has been renewed.

Status Date: Aug. 19, 2011

Publication Date: May 05, 1981

Mark Information

Mark Literal Elements: APOTEX

Standard Character Claim: No

Mark Drawing Type: 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Foreign Information

Foreign Application Number: 417,984

Foreign Application Filing Date: Nov. 23, 1977

Foreign Registration Number: 241,324

Foreign Registration Date: Mar. 21, 1980

Foreign Application/Registration Country: CANADA

Foreign Expiration Date: Mar. 21, 1995

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((.)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Medicinal and Pharmaceutical Preparations

International Class(es): 005 - Primary Class

U.S Class(es): 018

Class Status: ACTIVE

Basis: 44(e)

Basis Information (Case Level)

Filed Use: No

Currently Use: No

Amended Use: No

Filed ITU: No	Currently ITU: No	Amended ITU: No
Filed 44D: Yes	Currently 44D: No	Amended 44D: No
Filed 44E: Yes	Currently 44E: Yes	Amended 44E: No
Filed 66A: No	Currently 66A: No	
Filed No Basis: No	Currently No Basis: No	

Current Owner(s) Information

Owner Name: APOTEX TECHNOLOGIES, INC.
Owner Address: 150 SIGNET DRIVE
TORONTO, ONTARIO M9L 1T9
CANADA
Legal Entity Type: CORPORATION
State or Country Where Organized: CANADA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Robert W. Adams
Attorney Primary Email Address: fbe@nixonvan.com
Docket Number: 2148-107
Attorney Email Authorized: Yes

Correspondent

Correspondent Name/Address: Robert W. Adams
Nixon & Vanderhye, P.C.
901 North Glebe Rd., 11th Floor
Arlington, VIRGINIA 22203-1808
UNITED STATES
Phone: 703-816-4022
Fax: 703-816-4100
Correspondent e-mail: fbe@nixonvan.com
Correspondent e-mail Authorized: Yes

Domestic Representative

Domestic Representative Name: Robert W. Adams
Domestic Representative e-mail: fbe@nixonvan.com
Phone: 703-816-4022
Fax: 703-816-4100
Domestic Representative e-mail Authorized: Yes

Prosecution History

Date	Description	Proceeding Number
Aug. 19, 2011	REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)	67603
Aug. 19, 2011	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	67603
Aug. 11, 2011	REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED	67603
Aug. 11, 2011	PAPER RECEIVED	
Aug. 10, 2011	ATTORNEY REVOKED AND/OR APPOINTED	
Aug. 10, 2011	TEAS REVOKE/APPOINT ATTORNEY RECEIVED	
Aug. 10, 2011	TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS	
Mar. 16, 2009	CASE FILE IN TICRS	
Oct. 17, 2001	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	
Oct. 17, 2001	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	
Jul. 27, 2001	REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED	
Sep. 20, 1988	REGISTERED - SEC. 8 (6-YR) ACCEPTED	
Aug. 29, 1988	RESPONSE RECEIVED TO POST REG. ACTION	
Feb. 23, 1988	POST REGISTRATION ACTION MAILED - SEC. 8	
Jul. 27, 1987	REGISTERED - SEC. 8 (6-YR) FILED	
Jul. 28, 1981	REGISTERED-PRINCIPAL REGISTER	

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Renewal Date: Jul. 28, 2011

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: GENERIC WEB UPDATE

Date in Location: Aug. 19, 2011

Assignment Abstract Of Title Information

Summary

Total Assignments: 1

Registrant: APOTEX INC.

Assignment 1 of 1

Conveyance: ASSIGNS THE ENTIRE INTEREST

Reel/Frame: [3198/0369](#)

Pages: 4

Date Recorded: Nov. 22, 2005

Supporting Documents: [assignment-tm-3198-0369.pdf](#)

Assignor

Name: [APOTEX, INC.](#)

Execution Date: Nov. 18, 2005

Legal Entity Type: CORPORATION

State or Country Where Organized: CANADA

Assignee

Name: [APOTEX TECHNOLOGIES, INC.](#)

Legal Entity Type: CORPORATION

State or Country Where Organized: CANADA

Address: 150 SIGNET DRIVE
TORONTO, ONTARIO, CANADA M9L 1T9

Correspondent

Correspondent Name: ROBERT W. ADAMS

Correspondent Address: 901 NORTH GLEBE ROAD
11TH FLOOR
ARLINGTON, VA 22203-1808

Domestic Representative

Domestic Representative Name: ROBERT W. ADAMS

Domestic Representative Address: 901 NORTH GLEBE ROAD
11TH FLOOR
ARLINGTON, VA 22203-1808

Int. Cl.: 5

Prior U.S. Cl.: 18

United States Patent and Trademark Office

Reg. No. 1,162,404

Registered Jul. 28, 1981

TRADEMARK
Principal Register

APOTEX

Apotex Inc. (Canada corporation)
406 Ormont Dr.
Weston, Ontario, M9L 1N9, Canada

For: **MEDICINAL AND PHARMACEUTICAL PREPARATIONS**, in CLASS 5 (U.S. Cl. 18).

Priority claimed under Sec. 44(d) on Canada application No. 417,984, filed Nov. 23, 1977, Reg. No. 241,324, dated Mar. 21, 1980, expires Mar. 21, 1995.

Ser. No. 162,271, filed Mar. 15, 1978.

ROY H. NEILSON, Primary Examiner

EXHIBIT 3

Generated on: This page was generated by TSDR on 2016-03-18 15:23:07 EDT

Mark: APOBIOLOGIX A DIVISION OF APOTEX CORP.



US Serial Number: 76713573

Application Filing Date: Feb. 25, 2013

US Registration Number: 4632563

Registration Date: Nov. 04, 2014

Register: Principal

Mark Type: Service Mark

Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.

Status Date: Nov. 04, 2014

Publication Date: Jul. 02, 2013

Notice of Allowance Date: Aug. 27, 2013

Mark Information

Mark Literal Elements: APOBIOLOGIX A DIVISION OF APOTEX CORP.

Standard Character Claim: No

Mark Drawing Type: 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)

Description of Mark: The mark consists of the stylized figure of a human being to the left of a stylized rendering of the word "ApoBiologix" with the letters "A" and "B" presented in initial caps and the remaining letters presented in lower case lettering. Beneath separated by a horizontal line the length of the wording and flush to the right is the wording "A Division of Apotex Corp." in a smaller font with the letters "A", "D", and "C" in the wording featured in initial caps and the remaining letters in lower case.

Color(s) Claimed: Color is not claimed as a feature of the mark.

Disclaimer: "A DIVISION OF" AND "CORP."

Design Search Code(s): 02.01.33 - Grotesque men formed by letters, numbers, punctuation or geometric shapes; Stick figures
04.07.03 - Geometric figures or combinations of geometric figures representing a person; Geometric figures representing a person; Geometric shapes forming a person; Person formed by geometric shapes
26.01.21 - Circles that are totally or partially shaded.
26.17.09 - Bands, curved; Lines, curved; Curved line(s), band(s) or bar(s); Bars, curved
26.17.12 - Angles (geometric); Chevrons
26.17.13 - Overlined words or letters; Letters or words underlined and/or overlined by one or more strokes or lines; Underlined words or letters

Related Properties Information

Claimed Ownership of US Registrations: 1162404, 2859839 and others

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((.)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Drug product research development services

International Class(es): 042 - Primary Class

U.S Class(es): 100, 101

Class Status: ACTIVE

Basis: 1(a)

First Use: Aug. 18, 2014

Use in Commerce: Aug. 18, 2014

Basis Information (Case Level)

Apr. 17, 2013	ASSIGNED TO LIE	69712
Apr. 10, 2013	PAPER RECEIVED	
Mar. 19, 2013	NON-FINAL ACTION MAILED	
Mar. 18, 2013	NON-FINAL ACTION WRITTEN	76738
Mar. 13, 2013	ASSIGNED TO EXAMINER	76738
Mar. 05, 2013	APPLICATION FILING RECEIPT MAILED	
Feb. 28, 2013	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: PUBLICATION AND ISSUE SECTION

Date in Location: Sep. 29, 2014

United States of America

United States Patent and Trademark Office



Reg. No. 4,632,563

APOTEX TECHNOLOGIES INC. (CANADA CORPORATION)
150 SIGNET DRIVE

Registered Nov. 4, 2014

TORONTO, ONTARIO, CANADA M9L 1T9

Int. Cl.: 42

FOR: DRUG PRODUCT RESEARCH DEVELOPMENT SERVICES, IN CLASS 42 (U.S. CLS. 100 AND 101).

SERVICE MARK

FIRST USE 8-18-2014; IN COMMERCE 8-18-2014.

PRINCIPAL REGISTER

OWNER OF U.S. REG. NOS. 1,162,404, 2,859,839, AND OTHERS.

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "A DIVISION OF" AND "CORP.", APART FROM THE MARK AS SHOWN.

THE MARK CONSISTS OF THE STYLIZED FIGURE OF A HUMAN BEING TO THE LEFT OF A STYLIZED RENDERING OF THE WORD "APOBIOLOGIX" WITH THE LETTERS "A" AND "B" PRESENTED IN INITIAL CAPS AND THE REMAINING LETTERS PRESENTED IN LOWER CASE LETTERING. BENEATH SEPARATED BY A HORIZONTAL LINE THE LENGTH OF THE WORDING AND FLUSH TO THE RIGHT IS THE WORDING "A DIVISION OF APOTEX CORP." IN A SMALLER FONT WITH THE LETTERS "A", "D", AND "C" IN THE WORDING FEATURED IN INITIAL CAPS AND THE REMAINING LETTERS IN LOWER CASE.



SN 76-713,573, FILED 2-25-2013.

KHANH LE, EXAMINING ATTORNEY

Michelle K. Lee

Deputy Director of the United States
Patent and Trademark Office

**REQUIREMENTS TO MAINTAIN YOUR FEDERAL
TRADEMARK REGISTRATION**

**WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE
DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.**

Requirements in the First Ten Years*

What and When to File:

First Filing Deadline: You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.

Second Filing Deadline: You must file a Declaration of Use (or Excusable Nonuse) **and** an Application for Renewal between the 9th and 10th years after the registration date.*
See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

You must file a Declaration of Use (or Excusable Nonuse) **and** an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

**The United States Patent and Trademark Office (USPTO) will NOT send you any future notice or
reminder of these filing requirements.**

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the USPTO. The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

EXHIBIT 4

Generated on: This page was generated by TSDR on 2016-03-18 15:25:02 EDT

Mark: APOBIOLOGIX



US Serial Number: 76713572

Application Filing Date: Feb. 25, 2013

US Registration Number: 4621329

Registration Date: Oct. 14, 2014

Register: Principal

Mark Type: Service Mark

Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.

Status Date: Oct. 14, 2014

Publication Date: Jun. 25, 2013

Notice of Allowance Date: Aug. 20, 2013

Mark Information

Mark Literal Elements: APOBIOLOGIX

Standard Character Claim: No

Mark Drawing Type: 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)

Description of Mark: The mark consists of the stylized figure of a human being to the left of a stylized rendering of the word "ApoBiologix" with the letters "A" and "B" presented in initial caps and the remaining letters presented in lower case lettering.

Color(s) Claimed: Color is not claimed as a feature of the mark.

Design Search Code(s): 02.01.33 - Grotesque men formed by letters, numbers, punctuation or geometric shapes; Stick figures
04.07.03 - Geometric figures or combinations of geometric figures representing a person; Geometric figures representing a person; Geometric shapes forming a person; Person formed by geometric shapes
26.01.21 - Circles that are totally or partially shaded.
26.17.09 - Bands, curved; Bars, curved; Curved line(s), band(s) or bar(s); Lines, curved
26.17.12 - Angles (geometric); Chevrons

Related Properties Information

Claimed Ownership of US Registrations: 1162404, 2859839 and others

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *.* identify additional (new) wording in the goods/services.

For: Drug product research development services

International Class(es): 042 - Primary Class

U.S Class(es): 100, 101

Class Status: ACTIVE

Basis: 1(a)

First Use: Aug. 18, 2014

Use in Commerce: Aug. 18, 2014

Basis Information (Case Level)

Filed Use: No

Currently Use: Yes

Amended Use: No

Filed ITU: Yes

Currently ITU: No

Amended ITU: No

Filed 44D: No

Currently 44D: No

Amended 44D: No

Filed 44E: No
Filed 66A: No
Filed No Basis: No

Currently 44E: No
Currently 66A: No
Currently No Basis: No

Amended 44E: No

Current Owner(s) Information

Owner Name: APOTEX TECHNOLOGIES INC.
Owner Address: 150 Signet Drive
Toronto, Ontario M9L 1T9
CANADA
Legal Entity Type: CORPORATION
State or Country Where Organized: CANADA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Robert W. Adams
Docket Number: 2148-122

Correspondent

Correspondent Name/Address: ROBERT W. ADAMS
NIXON & VANDERHYE P.C.
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VIRGINIA 22203-1808
UNITED STATES
Phone: 703-816-4022
Fax: 703-816-4100

Domestic Representative

Domestic Representative Name: Nixon & Vanderhye, P.C.
Phone: (703) 816-4022
Fax: (703) 816-4100

Prosecution History

Date	Description	Proceeding Number
Oct. 14, 2014	REGISTERED-PRINCIPAL REGISTER	
Sep. 06, 2014	NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED	
Sep. 05, 2014	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED	
Aug. 24, 2014	STATEMENT OF USE PROCESSING COMPLETE	65362
Aug. 20, 2014	USE AMENDMENT FILED	65362
Aug. 20, 2014	TEAS STATEMENT OF USE RECEIVED	
Feb. 22, 2014	NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED	
Feb. 20, 2014	EXTENSION 1 GRANTED	98765
Feb. 20, 2014	EXTENSION 1 FILED	98765
Feb. 20, 2014	TEAS EXTENSION RECEIVED	
Sep. 25, 2013	APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED	65362
Sep. 24, 2013	CASE ASSIGNED TO INTENT TO USE PARALEGAL	65362
Aug. 26, 2013	FAX RECEIVED	
Aug. 20, 2013	NOA MAILED - SOU REQUIRED FROM APPLICANT	
Jun. 25, 2013	PUBLISHED FOR OPPOSITION	
Jun. 05, 2013	NOTICE OF PUBLICATION	
May 23, 2013	LAW OFFICE PUBLICATION REVIEW COMPLETED	68171
May 23, 2013	ASSIGNED TO LIE	68171
May 14, 2013	APPROVED FOR PUB - PRINCIPAL REGISTER	
May 10, 2013	EXAMINERS AMENDMENT MAILED	
May 09, 2013	EXAMINER'S AMENDMENT ENTERED	88888
May 09, 2013	EXAMINERS AMENDMENT -WRITTEN	76738
Apr. 18, 2013	AMENDMENT FROM APPLICANT ENTERED	68552
Apr. 18, 2013	CORRESPONDENCE RECEIVED IN LAW OFFICE	68552
Apr. 11, 2013	ASSIGNED TO LIE	68552

Apr. 08, 2013	PAPER RECEIVED	
Mar. 19, 2013	NON-FINAL ACTION MAILED	
Mar. 18, 2013	NON-FINAL ACTION WRITTEN	76738
Mar. 13, 2013	ASSIGNED TO EXAMINER	76738
Mar. 05, 2013	APPLICATION FILING RECEIPT MAILED	
Feb. 28, 2013	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: PUBLICATION AND ISSUE SECTION

Date in Location: Sep. 05, 2014

United States of America

United States Patent and Trademark Office



Reg. No. 4,621,329

APOTEX TECHNOLOGIES INC. (CANADA CORPORATION)
150 SIGNET DRIVE

Registered Oct. 14, 2014

TORONTO, ONTARIO, CANADA M9L 1T9

Int. Cl.: 42

FOR: DRUG PRODUCT RESEARCH DEVELOPMENT SERVICES, IN CLASS 42 (U.S. CLS. 100 AND 101).

SERVICE MARK

FIRST USE 8-18-2014; IN COMMERCE 8-18-2014.

PRINCIPAL REGISTER

OWNER OF U.S. REG. NOS. 1,162,404, 2,859,839, AND OTHERS.

THE MARK CONSISTS OF THE STYLIZED FIGURE OF A HUMAN BEING TO THE LEFT OF A STYLIZED RENDERING OF THE WORD "APOBIOLOGIX" WITH THE LETTERS "A" AND "B" PRESENTED IN INITIAL CAPS AND THE REMAINING LETTERS PRESENTED IN LOWER CASE LETTERING.

SN 76-713,572, FILED 2-25-2013.

KHANH LE, EXAMINING ATTORNEY



Michelle K. Lee

Deputy Director of the United States
Patent and Trademark Office

**REQUIREMENTS TO MAINTAIN YOUR FEDERAL
TRADEMARK REGISTRATION**

**WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE
DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.**

Requirements in the First Ten Years*
What and When to File:

First Filing Deadline: You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.

Second Filing Deadline: You must file a Declaration of Use (or Excusable Nonuse) **and** an Application for Renewal between the 9th and 10th years after the registration date.*
See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*
What and When to File:

You must file a Declaration of Use (or Excusable Nonuse) **and** an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

**The United States Patent and Trademark Office (USPTO) will NOT send you any future notice or
reminder of these filing requirements.**

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the USPTO. The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.